Clinical Trials Logo

Metastatic Neuroendocrine Tumor clinical trials

View clinical trials related to Metastatic Neuroendocrine Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04234568 Active, not recruiting - Clinical trials for Metastatic Neuroendocrine Tumor

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Start date: July 20, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. Giving triapine and lutetium Lu 177 dotatate together may work better to treat patients with neuroendocrine tumors.

NCT ID: NCT01841736 Active, not recruiting - Clinical trials for Metastatic Digestive System Neuroendocrine Tumor G1

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Start date: September 20, 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.